| Overview |
| bs-18190R-FITC |
| LCLAT1 Polyclonal Antibody, FITC Conjugated |
| WB, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Mouse, Rat |
| Human, Dog, Cow, Sheep, Horse, Rabbit |
| Specifications |
| FITC |
| Rabbit |
| KLH conjugated synthetic peptide derived from human LCLAT1 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 253558 |
| Q6UWP7 |
| Cytoplasm |
| Lysocardiolipin acyltransferase 1; LCLAT1; 1-acylglycerol-3-phosphate O-acyltransferase 8; 1-AGP acyltransferase 8; 1-AGPAT 8; Acyl-CoA:lysocardiolipin acyltransferase 1; LCLAT1; AGPAT8; ALCAT1; LYCAT; UNQ1849/PRO3579 |
| Acyl-CoA:lysocardiolipin acyltransferase. Possesses both lysophosphatidylinositol acyltransferase (LPIAT) and lysophosphatidylglycerol acyltransferase (LPGAT) activities. Recognizes both monolysocardiolipin and dilysocardiolipin as substrates with a preference for linoleoyl-CoA and oleoyl-CoA as acyl donors. Acts as a remodeling enzyme for cardiolipin, a major membrane polyglycerophospholipid. Converts lysophosphatidic acid (LPA) into phosphatidic acid (PA) with a relatively low activity. Required for establishment of the hematopoietic and endothelial lineages. |
| Application Dilution |
| WB |
1:300-5000 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz